Accendra Health, Inc. has received a notice of non-compliance from the New York Stock Exchange (NYSE) regarding its continued listing standards. According to the filing dated October 6, 2026, the exchange notified the company that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual. This non-compliance stems from the fact that the average closing price of the company's Common Stock was less than $1.00 per share over a consecutive 30 trading-day period.
The notice does not result in the immediate delisting of the company's shares. The Common Stock will continue to be listed and trade on the NYSE during this period, provided the company maintains compliance with all other continued listing requirements.
Under NYSE rules, the company has a six-month period following the receipt of the notice to regain compliance with the minimum share price requirement. The company intends to notify the NYSE within ten business days of the notice to affirm its intent to cure the deficiency. To regain compliance, the company must achieve a closing share price of at least $1.00 and an average closing price of at least $1.00 over a 30 trading-day period ending on the last trading day of any calendar month during the cure period.
The company stated that it intends to consider a number of available alternatives to cure the deficiency. These alternatives include, if necessary, a reverse stock split. Any reverse stock split would be subject to stockholder approval no later than at the company's next annual meeting of stockholders, which is anticipated to take place in May 2027.
The company noted that the receipt of the notice does not affect its business operations or its reporting obligations with the Securities and Exchange Commission.
